Comparison 15. 595‐nm Pulsed‐Dye Laser (PDL) plus intralesional verapamil versus intralesional verapamil.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
15.1 Incidence of treatment‐related adverse effects (24 weeks)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
15.1.1 Regrowth (24 weeks)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
15.1.2 Treatment‐related pain (24 weeks)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
15.1.3 Hyperpigmentation (24 weeks)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
15.1.4 Depigmentation (24 weeks)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
15.1.5 Purpura (24 weeks)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
15.1.6 Total (24 weeks)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
15.2 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (change from baseline) (12 weeks)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
15.2.1 Height (12 weeks)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
15.2.2 Vascularity (12 weeks)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
15.2.3 Pliability (12 weeks)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
15.2.4 Pigmentation (12 weeks)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
15.3 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain (change from baseline) (24 weeks)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
15.3.1 Height (24 weeks)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
15.3.2 Vascularity (24 weeks)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
15.3.3 Pliability (24 weeks)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
15.3.4 Pigmentation (24 weeks)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected